
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Washington - Topical application of tazarotene 0.05 percent was effective in reducing cutaneous roughness and scaling in a patient with a rare form of ichthyosis known as Rud's syndrome, according to Maria Concetta Fargnoli, M.D., a dermatologist at the University of L'Aquila, Italy.